NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the details of its participation at the ESMO Immuno-Oncology Congress on December 13-16, 2018 at the Palexpo Exhibition Center, 30 Route François-Peyrot, 1218 Le Grand-Saconnex, in Geneva, Switzerland.
Poster Title: Safety and clinical outcome in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab
The poster will be presented on Friday, December 14 from 12.30-01.00 p.m. CET in Room B and the authors will be available for questions. The poster will also be uploaded to the NOXXON website.
The abstract which is based on an earlier interim dataset will be published on Monday, December 10 at 12.00 p.m. CET on the ESMO website.
Lead investigator of the trial, Dr. Niels Halama, will discuss some of the results from the poster in a presentation entitled “A goal for immunotherapy in pancreatic cancer” on Sunday, December 16, from 09.50-10.10 a.m. CET in Room A.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.